Outcome of Board Meeting dated 03.12.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Astonea Labs' board approved the AGM notice and Directors' Report for FY 2024-25, setting the stage for the upcoming annual general meeting. Key people moves include the appointment of Mr. Ankit Kapoor as Company Secretary and Compliance Officer, and the retirement-by-rotation of director Mr. Pardeep Singh, who will not seek re-appointment. Strategically, the board approved acquiring an equity stake in Damaira Pharmaceuticals Private Limited and authorised investments in multiple foreign/overseas subsidiaries, signalling expansion plans. The company will voluntarily shift its financial reporting from Indian Accounting Standards (AS) to Ind AS starting FY 2026-27. The board also cleared the relocation of its corporate office within Panchkula, Haryana, and adopted a suite of governance policies including Vigil Mechanism, RPT Policy, Code of Conduct, and Material Subsidiaries Policy. KFin Technologies was engaged to handle e-voting for the AGM.
The acquisition of Damaira Pharmaceuticals and plans to set up foreign subsidiaries are the most material items here and could positively affect long-term growth, though deal terms and size were not disclosed. Routine governance updates and the planned Ind AS transition reflect improving compliance standards, with no immediate effect on share price expected.